Denmark-based biopharmaceutical firm Novo Nordisk will cease all its R&D programs in small molecules for the oral treatment of diabetes and will focus instead on its protein-based pharmaceuticals.

"Our core competences lie within therapeutic proteins, and it is within this area that we can make the greatest difference in terms of patient outcomes and company growth. Therefore, it is a logical move to focus all our research and development efforts on this area."

All existing projects on small molecules, including NN9101, a glucokinase activator currently in phase 1 clinical testing, may be out-licensed.

Source: Novo Nordisk